

# ZOOMMED

EMPOWERING DOCTORS



THE ZRX PRESCRIBER: THE MAGIC OF A FAST ACCESS AND EFFICIENT COMPENDIUM

**INTERIM CONSOLIDATED FINANCIAL REPORT  
AS AT NOVEMBER 30, 2011 AND 2010**

---

<b>MANAGEMENT COMMENTS</b>	2
<b>INTERIM CONSOLIDATED FINANCIAL REPORT (unaudited)</b>	
Consolidated balance sheets	3
Interim consolidated statements of changes in equity	4
Interim consolidated statements of income	5
Interim consolidated statements of cash flows	6
Notes to interim consolidated financial statements	7 - 27

**To the shareholders of  
ZOOMMED INC.**

**MANAGEMENT COMMENTS**

The interim consolidated financial report of ZoomMed Inc. for the periods ended November 30, 2011 and 2010 and all information contained in this interim consolidated financial report is the responsibility of the management and has been approved by the Board of Directors.

The consolidated interim financial report was prepared by the management in accordance with International Financial Reporting Standards ("IFRS") and is consistent with the Company's business.

The Company complies with its TSX Venture Exchange listing agreement. The Company maintains rigorous systems of internal accounting and administrative controls to provide reasonable assurance that the financial information is relevant, reliable and accurate and that the assets are correctly accounted for and protected.

Every year the Board of Directors appoints an Audit Committee composed of a majority of directors who are neither Company officers nor employees. The Audit Committee meets periodically with Management and the external auditors to review their tasks and discuss the audit, accounting policies and related financial matters. The results of their audit are discussed as well. The Audit Committee also reviews the financial statements and the independent auditors' report and recommends their approval by the Board of Directors.

The interim consolidated financial report for the six-month periods ended November 30, 2011 and November 30, 2010, has not been reviewed or audited by independent auditors.

January 23, 2012



**Yves Marmet,**  
President and Chief Executive Officer



**CONSOLIDATED BALANCE SHEETS**  
**AS AT NOVEMBER 30, 2011, MAY 31, 2011 AND JUNE 1<sup>ST</sup> 2010**  
**(unaudited)**

	November 30, 2011 (unaudited) \$	May 31, 2011 (unaudited) \$	June 1, 2010 (unaudited) \$
<b>ASSETS</b>			
<b>Current assets</b>			
Cash	328,610	1,698,024	2,632,065
Accounts receivables and other receivables (Note 7)	1,540,635	210,904	411,648
Prepaid expenses	31,445	32,395	30,771
	1,900,690	1,941,323	3,074,484
<b>Non-current assets</b>			
Fixed assets (Note 8)	351,505	444,356	567,576
Intangible assets (Note 9)	3,067,444	2,944,885	1,792,830
<b>Total assets</b>	<b>5,319,639</b>	<b>5,330,564</b>	<b>5,434,890</b>
<b>LIABILITIES</b>			
<b>Current liabilities</b>			
Accounts payable and accrued liabilities (Note 10)	705,072	908,204	641,055
Deferred revenue	1,430,390	1,043,474	958,833
	2,135,462	1,951,678	1,599,888
<b>Non-current liabilities</b>			
Lease inducement	2,177	3,628	7,759
Convertible debenture (Note 11)	1,500,000	-	-
<b>Total liabilities</b>	<b>3,637,638</b>	<b>1,955,306</b>	<b>1,607,647</b>
<b>SHAREHOLDERS' EQUITY</b>			
Share capital (Note 14)	25,438,120	25,438,120	23,001,758
Warrants (Note 16)	768,676	768,676	1,794,661
Contributed surplus	5,425,141	5,350,723	3,065,176
Deficit	(29,949,937)	(28,182,261)	(24,034,352)
<b>Total equity</b>	<b>1,682,000</b>	<b>3,375,258</b>	<b>3,827,243</b>
<b>Total liabilities and equity</b>	<b>5,319,639</b>	<b>5,330,564</b>	<b>5,434,890</b>

**ON BEHALF OF THE BOARD OF DIRECTORS**

*Marie-Stéphanie Proulx*

Director

*Jos Harriet*

Director



**INTERIM CONSOLIDATED STATEMENT OF CHANGES IN EQUITY  
FOR THE THREE-MONTH AND SIX-MONTH PERIODS ENDED NOVEMBER 30, 2011 AND 2010  
(unaudited)**

(unaudited)	Share capital	Warrants	Contributed surplus	Deficit	Total
	\$	\$	\$	\$	\$
<b>Balance as at June 1, 2011</b>	25,438,120	768,676	5,350,723	(28,182,261)	3,375,258
Net loss	-	-	-	(1,767,676)	(1,767,676)
Share issue expenses	-	-	-	-	-
Fair value of stock options granted	-	-	74,418	-	74,418
Fair value of units granted to agents	-	-	-	-	-
Expired warrants	-	-	-	-	-
<b>Balance as at November 30, 2011</b>	25,438,120	768,676	5,425,141	(29,949,937)	1,682,000
(unaudited)					
<b>Balance as at June 1, 2010</b>	23,001,758	1,794,661	3,065,176	(24,034,351)	3,827,244
Net loss	-	-	-	(1,896,579)	(1,896,579)
Share issue expenses	-	-	-	(3,393)	(3,393)
Fair value of stock options granted	-	-	-	-	-
Fair value of units granted to agents	-	-	-	-	-
Expired warrants	-	(1,794,661)	1,794,661	-	-
<b>Balance as at November 30, 2010</b>	23,001,758	-	4,859,837	(25,934,323)	1,927,272



**INTERIM CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME  
FOR THE THREE-MONTH AND SIX-MONTH PERIODS ENDED NOVEMBER 30, 2011 AND 2010  
(unaudited)**

	November 30, 2011 (3 months) (unaudited) \$	November 30, 2010 (3 months) (unaudited) \$	November 30, 2011 (6 months) (unaudited) \$	November 30, 2010 (6 months) (unaudited) \$
<b>REVENUE</b> (Note 12)	701,231	500,826	1,266,870	1,041,820
<b>OPERATING EXPENSES</b> (Note 12)				
Selling expenses	387,944	299,774	659,110	587,120
Administrative expenses	443,567	501,709	788,158	952,018
General operating expenses	277,726	297,209	584,751	583,130
Development Costs	201,758	255,256	456,051	422,923
Financial expenses	215,419	1,536	219,041	5,516
Amortization	186,662	227,120	327,436	387,692
	1,713,076	1,582,604	3,034,546	2,938,399
<b>LOSS BEFORE INCOME TAXES</b>	(1,011,845)	(1,081,778)	(1,767,676)	(1,896,579)
<b>INCOME TAXES</b>	-	-	-	-
<b>NET LOSS AND COMPREHENSIVE LOSS</b>	(1,011,845)	(1,081,778)	(1,767,676)	(1,896,579)
<b>BASIC AND DILUTED EARNINGS PER SHARE</b>	(0.008)	(0.010)	(0.014)	(0.017)
<b>WEIGHTED AVERAGE NUMBER OF OUTSTANDING COMMON SHARE</b>	130,474,687	110,841,785	130,474,687	110,841,785



**INTERIM CONSOLIDATED STATEMENTS OF CASH FLOWS**  
**FOR THE THREE-MONTH AND SIX-MONTH PERIODS ENDED NOVEMBER 30, 2011 ET 2010**  
**(unaudited)**

	November 30, 2011 (3 months) (unaudited) \$	November 30, 2010 (3 months) (unaudited) \$	November 30, 2011 (6 months) (unaudited) \$	November 30, 2010 (6 months) (unaudited) \$
<b>OPERATING ACTIVITIES</b>				
Net loss	(1,011,845)	(1,081,778)	(1,767,676)	(1,896,579)
Amortization	186,662	227,121	327,435	387,692
Stock-based compensation	74,748	-	74,418	-
Loss (gain) on disposal of fixed assets	(13,701)	(1,044)	(28,827)	7,623
Lease inducements	(725)	(1,185)	(1,451)	(2,372)
	(765,191)	(856,886)	(1,396,101)	(1,503,636)
Net change in non-cash operating working capital items	(487,065)	263,726	(1,144,996)	(113,538)
Cash flows used in operating activities	(1,252,256)	(593,160)	(2,541,097)	(1,617,174)
<b>FINANCING ACTIVITIES</b>				
Share issue expenses	-	-	-	(3,393)
Convertible debenture	1,500,000	-	1,500,000	-
Cash flows from financing activities	1,500,000	-	1,500,000	(3,393)
<b>INVESTING ACTIVITIES</b>				
Acquisition of fixed assets	(10,814)	(95,838)	(43,807)	(149,671)
Proceeds from disposal of fixed assets	17,181	13,223	34,024	53,642
Acquisition of intangible assets	(166,663)	(43,073)	(318,534)	(142,015)
Cash flows used in investing activities	(160,296)	(125,688)	(328,317)	(238,044)
<b>NET CHANGE IN CASH</b>	87,448	(718,848)	(1,369,414)	(1,858,611)
<b>CASH, BEGINNING OF YEAR</b>	241,162	1,492,302	1,698,024	2,632,065
<b>CASH, END OF YEAR</b>	328,610	773,454	328,610	773,454



**NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS  
FOR THE THREE-MONTH AND SIX-MONTH PERIODS ENDED NOVEMBER 30, 2011 ET 2010  
(unaudited)**

---

**1. GENERAL INFORMATION**

ZoomMed Inc. ("ZoomMed") was incorporated under the Canada Business Corporations Act on February 24, 2005.

ZoomMed Inc. and its subsidiaries (the "Company") are committed to the development and the marketing of an extended drug information system network; "the e-Pic network".

The e-Pic network aggregates communications and allows patients, physicians, pharmacists and pharmaceutical corporations to interact, thus enhancing health care stakeholder's efficiency.

As part of this network, the Company developed and markets the ZRx Prescriber, a technological innovative Web application that enables physicians to use a wireless device, such as the IPod Touch, iPhone, iPad, Google Android, other PDA's or computers, to write and rapidly deliver scripts to pharmacies.

The ZRx Prescriber is quick, efficient and intuitive. Since it is a stand-alone product, it can easily be integrated to any Electronic Medical Record application (EMR). The ZRx Prescriber is also, for the physician, a mobile source of information coming from pharmaceutical corporations, as well as private and public institutions.

Furthermore, the Company develops and markets a new application that enhances all aspects of the prescription filling process and the complete pharmacists patient file management "PraxisLab". PraxisLab uses up-to-date Web technology which is perfectly compatible with the technology used by the Company.

The ensuing communication and management improvement enhances the health care system and allows patients to have access to faster and more secure services.

ZoomMed Inc. common shares are trading on the TSX Venture Exchange under ZMD symbol.

The Company's registered head office is located at 6300 Auteuil Street, Suite 121, Brossard, Québec, Canada, J4Z 3P2.

**2. BASIS OF PRESENTATION OF FINANCIAL STATEMENTS AND ADOPTION OF IFRS**

The Company prepares its financial statements in accordance with Canadian generally accepted accounting principles as set out in the Handbook of the Canadian Institute of Chartered Accountants ("CICA Handbook"). In 2010, the CICA Handbook was revised to incorporate International Financial Reporting Standards ("IFRS"), and require publicly accountable enterprises to apply such standards effective for fiscal years beginning on or after January 1, 2011. Accordingly, the Company has commenced reporting on this basis in these interim consolidated financial statements. In the financial statements, the term "Canadian GAAP" refers to Canadian GAAP before the adoption of IFRS.

These financial statements have been prepared in accordance with Canadian generally accepted accounting principles that are applicable to a going concern. Under the going concern assumption, a company is viewed as being able to continue its operations in the foreseeable future and realize its assets and discharge its liabilities in the normal course of operations.

The continuation and growth of the Company's activities depend on its ability to gain profitability and to obtain additional financing or cash provided by operations. These funds will come from share issue, either from public or private placement or strategic alliances, or other financing sources. At this stage, it is impossible to predict, at this stage, if those elements will materialize.

The interim consolidated financial statements do not reflect adjustments that should be made to the book value of assets and liabilities in the case where the Company would be unable to realize its assets and discharge its liabilities in the normal course of operations.





**NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS  
FOR THE THREE-MONTH AND SIX-MONTH PERIODS ENDED NOVEMBER 30, 2011 ET 2010  
(unaudited)**

---

**2. BASIS OF PRESENTATION OF FINANCIAL STATEMENTS AND ADOPTION OF IFRS (CONT.)**

These interim consolidated financial statements have been prepared in accordance with IFRS applicable to the preparation of interim financial statements, including IAS 34 "Interim financial Reporting" and IFRS 1 "First-time Adoption of International Financial Reporting Standards". Subject to certain transition elections disclosed in note 20, the Company has consistently applied the same accounting policies in its opening IRFS balance sheets as at June 1, 2010 and throughout all periods presented, as if these policies had always been in effect. Note 20 discloses the impact of the transition to IFRS on the Company's reported financial position, financial performance and cash flows, including the nature and effect of significant changes in accounting policies from those used in the Company's consolidated financial statements for the fiscal year ended May 31, 2011.

The policies applied in these interim consolidated financial statements are based on IFRS issued and outstanding as of October 21, 2011, which is the date of approval of the financial statements by the board of director. Any subsequent changes to IFRS that are given effect in the Company's annual consolidated financial statements for the fiscal year ending May 31, 2012 could result in restatement of these interim consolidated financial statements, including the transition adjustments recognized on change-over to IFRS.

The interim consolidated financial statements should be read in conjunction with the Company's Canadian GAAP annual financial statements for the fiscal year ended May 31, 2011, which are considered material in understanding these interim consolidated financial statement. Note 20 disclose IFRS information for the fiscal year ended May 31, 2011 not provided in the 2011 annual financial statements.

**3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES**

**Basis of measurement**

These interim consolidated financial statements have been prepared under the historical cost convention, except for other measurement bases, as indicated in the related notes.

**Consolidation**

The interim consolidated financial statements include the accounts of ZoomMed Inc. and its subsidiaries ZoomMed Medical Inc., Praxis Santé Inc., 9205-1051 Quebec Inc. and ZoomMed USA Inc. Praxis Santé Inc. and 9205-1051 Quebec Inc. subsidiaries have transferred their activities to ZoomMed Medical Inc. following their acquisition.

**Revenue recognition**

In general, revenue are recognized to the extent that it is probable that the economic benefits will flow to the Company and the amount can be measured reliably. Revenue comprises the fair value of the consideration received or receivable for services in the ordinary course of the Company's activities.

Revenue derived from annual contracts, related to the e-Pic network, are recognized using the straight-line method over the duration of the agreements. As provided in these contracts, payments received in advance are recorded as deferred revenue in the Consolidated Statement of financial position, and then, as operating revenue as the service is rendered.

Interests' revenue are recorded on a fiscal year basis according to the effective interest rate method.

**Financial Instruments**

The classification and measurement of the financial instruments are determined as follows:

Financial assets at fair value through profit or loss

Cash and accounts receivables are presented as financial assets at fair value through profit and loss. They are measured at fair value and the fair value variations are recorded in the consolidated statements of comprehensive income, as financial income or financial expenses, during the period they occur.



**NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS  
FOR THE THREE-MONTH AND SIX-MONTH PERIODS ENDED NOVEMBER 30, 2011 ET 2010  
(unaudited)**

**3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.)**

Financial liabilities at fair value through profit or loss

Accounts payables are presented as financial liabilities at fair value through profit and loss. They are measured at fair value and the fair value variations are recorded in the consolidated statements of comprehensive income, as financial income or financial expenses, during the period they occur.

**Fixed assets**

Fixed assets are initially recorded at cost, including acquisition fees and all the preparation fees directly related to the asset before it can be used, less related research and development investment tax credits. Subsequent to the initial measurement, fixed assets are recorded at cost, less accumulated amortization and depreciation.

Amortization is recognized on a straight-line basis, in line with the assets useful life, as follows:

	<b>Method</b>	<b>Periods</b>
Furniture	Straight-line	5 years
Computer equipment	Straight-line	3 years
Computer equipment for ZRx Prescriber	Straight-line	3 years
Leasehold improvements	Straight-line	5 years

The Company allocates the amount initially recognized in respect of a fixed asset to its significant parts and depreciates separately each such part. Residual values, method of amortization and useful lives of the assets are reviewed annually and adjusted if appropriate.

Gain and losses on disposals of fixed assets are determined by comparing the proceeds with the carrying amount of the asset and are included as part of other gains and losses in the statement of income.

**Intangible assets**

The Company's intangible assets include Website, intellectual properties, licenses and rights, development costs and software with finite useful lives. These assets are capitalized and amortized on a straight-line basis in the statement of income over the period of their expected useful lives as follows:

	<b>Periods</b>
Website	3 years
Software	2 years
Intellectual properties	10 years
Licenses and rights	3 years
Development costs	3 years

Expenses related to development activities which do not meet generally accepted criteria for deferral and research activities are expensed as incurred. Development expenses which meet generally accepted criteria for deferral are capitalized and amortized against income over the estimated period of benefit.

The ZRx Prescriber intellectual property is recorded at cost and is amortized over a ten-year period from the marketing date of the product, which is November 2006. The PraxisLab intellectual property is recorded at cost and is amortized over a ten-year period from the date of acquisition.

The ZRx Prescriber development costs, which include the development of the e-Pic network and the additional new functionalities, according to future economic benefits, are amortized using the straight-line method over a three-year period from the implementation date of the product. PraxisLab development costs will be amortized using the straight-line method over a three-year period from the marketing date of the product.



**NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS  
FOR THE THREE-MONTH AND SIX-MONTH PERIODS ENDED NOVEMBER 30, 2011 ET 2010  
(unaudited)**

---

**3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.)**

**Research and development tax credits**

The Company is entitled to scientific research and development tax credits. Tax credits are accounted for using the cost reduction method. Accordingly, tax credits are recorded as a reduction of the related expenses or capital expenditures in the period in which those expenses are incurred, provided there is reasonable assurance that the credits will be realized.

**Impairment of long-term assets non-financial**

Items of identifiable tangible and intangible assets, with finite lives subject to depreciation or amortization respectively, are reviewed for impairment whenever events or changes in circumstances indicate that the carrying amounts of the assets may not be recoverable. Management is required to assess at each reporting date whether there is any indication that an asset may be impaired. Where such an indication exists, the asset's recoverable amount is compared to its carrying value and an impairment loss is recognized for the amount by which the asset's carrying amount exceeds its recoverable amount. The recoverable amount is the higher of an asset's fair value less costs to sell and value in use. For the purpose of assessing impairment, assets are grouped at the lowest levels for which there are separately identifiable cash flows or cash-generating units ("CGU"). In determining value in use of a given asset or CGU, estimated future cash flows are discounted to their present value using a pre-tax discount rate that reflects current market assessments of the time value of money and the risks specific to the asset.

Items of amortizable identifiable tangible and intangible assets with finite lives that suffered impairment are reviewed for possible reversal of the impairment if there has been a change, since the date of the most recent impairment test, in the estimates used to determine the impaired asset's recoverable amount. However, an asset's carrying amount, increased due to the reversal of a prior impairment loss, must not exceed the carrying amount that would have been determined, net of depreciation or amortization, had the original impairment not occurred.

**Lease inducement**

The lease inducement includes the difference between the rental expense apportioned over the lease term according to a systematic formula and the minimum lease payment, considering the inducements.

**Shareholder's Equity**

Common shares are classified as equity and are recorded in the Shareholder's Equity at their issuance value. Incremental costs directly attributable to the issuance of shares and stock options are shown in equity as a deduction (as a deficit increase) net of tax from the proceeds.

**Income taxes**

Income taxes are accounted for, by the Company, using the asset and liability method. Accordingly, future income tax assets and income tax liabilities are measured using the income tax rates that are most likely to apply during the fiscal year where the asset is realized or the liability is settled, based on the income tax rates (and tax regulations) adopted or nearly adopted as at the reporting date. As appropriate, a valuation allowance is recognized to decrease the value of future tax assets to an amount that is more likely than not to be realized.

**Stock-based compensation**

The Company offers a stock-based compensation plan. The Company uses the fair value based method of accounting as regards to stock options granted to its Officers, Directors, Employees and Consultants. The fair value of stock options is determined using the Black-Scholes option pricing model, and the stock-based compensation costs are recorded in the statements of income at the granted date and credited to contributed surplus.

Any consideration received by the Company in connection with the exercise of stock options is credited to share capital and contributed surplus component of the stock-based compensation is transferred to share capital upon the issuance of shares.



**NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS  
FOR THE THREE-MONTH AND SIX-MONTH PERIODS ENDED NOVEMBER 30, 2011 ET 2010  
(unaudited)**

---

**3. SUMMARY OF SIGNIFICANT ACCOUNTING POLICIES (CONT.)**

**Accounts denominated in foreign currencies**

Presentation currency and foreign currency operations

The Canadian dollars is the Company's presentation currency, which is also the Company's functional currency.

Foreign currency transactions are translated into the functional currency environment in which the entity operates using the exchange rates prevailing at the dates of the transactions. Assets and liabilities denominated in foreign currencies at the closing date are converted into functional currencies at the exchange rates prevailing at the same date. All resulting changes are recognized in the statement of income, except monetary items included into foreign institution net investment.

Foreign institutions

Foreign intuitions' assets and liabilities denominated in functional currencies other than Canadian dollars are converted into Canadian dollars using the exchange rates prevailing at the closing date. Foreign institution revenue and expenses are converted into Canadian dollars using the exchange rates prevailing at the date of the transaction. Shareholders equity is converted at the original effective rate prevailing at the closing date. All resulting changes are recognized in other comprehensive income until the net investment is disposed of, or reclassified in the statement of income. Since the transition date, no such resulting change was recorded as foreign institutions conversion adjustments.

**Basic and fully diluted earnings per share**

Basic and fully diluted earnings per share are determined using the weighted average number of outstanding common shares during the fiscal year. The Company uses the treasury stock method to determine the dilutive effects of stock options and warrants when cumulating diluted earnings per share. Accordingly, the calculation of diluted earnings per share is made using the treasury stock method, as if all potentially dilutive participating shares had been exercised at the later of the beginning of the period or the date of issuance, as the case may be, and that the funds obtained thereby had been used to purchase common shares of the company at the average market value of the common shares during the period.

The fully diluted earnings per share are equal to the basic earnings per share because of the anti dilutive effect of stock options and warrants when a loss is incurred.

**4. ACCOUNTING STANDARDS ISSUED BUT NOT YET APPLIED**

**Financial Instruments**

In November 2009, the IASB issued IFRS 9, "Financial Instruments", which represents the completion of the first part of a three-part project to replace IAS 39, "Financial Instruments: Recognition and Measurement", with a new standard. Per recent updates to IFRS 9, an entity choosing to measure a liability at fair value will present the portion of the change in its fair value due to changes in the entity's own credit risk in the other comprehensive income or loss section of the entity's statement of comprehensive loss, rather than within profit or loss. Additionally, IFRS 9 includes revised guidance related to the derecognition of financial instruments. IFRS 9 applies to financial statements for annual periods beginning on or after January 1, 2013, with early adoption permitted. The Company intends to adopt this new standard as at its effective date. The Company currently is evaluating any impact that this new guidance may have on the Company's consolidated financial statements.

**Reporting entity**

In May 2011, the IASB issued a group of five new standards that address the scope of the reporting entity: IFRS 10 "Consolidated financial statements", IFRS 11 "Joint arrangements", IFRS 12 "Disclosure of interests in other entities", IAS 27 "Separate financial statements" and IAS 28 "Investments in associates".



**NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS  
FOR THE THREE-MONTH AND SIX-MONTH PERIODS ENDED NOVEMBER 30, 2011 ET 2010  
(unaudited)**

---

**4. ACCOUNTING STANDARDS ISSUED BUT NOT YET APPLIED (CONT.)**

IFRS 10 replace all of the guidance on control and consolidation in IAS 27 “Consolidated and separate financial statements” and SIC-12 “Consolidation – special purpose entities”. IFRS 10 changes the definition of control so that the same criteria are applied to all entities to determine control focusing on the need to have both power and variable returns before control is present. Power is the current ability to direct the activities that significantly influence returns. Returns must vary and can be positive, negative or both. The renamed IAS 27 continues to be a standard dealing solely with separate financial statements and its guidance is unchanged.

IFRS 11 has changed the definitions of joint arrangements reducing the types of joint arrangements to two: joint operations and joint ventures. The existing policy choice of proportionate consolidation for jointly controlled entities has been eliminated and equity accounting is mandatory for all participants in joint ventures. Entities that participate in joint operations will follow an accounting method much like that for joint assets or joint operations today.

IFRS 12 sets out the required disclosures for entities reporting under IFRS 10 and IFRS 11 replacing the disclosure requirements currently found in IAS 18. IFRS 12 requires entities to disclose information that helps financial statement readers to evaluate the nature, risks and financial effects associated with the entity’s interests in subsidiaries, associates, joint arrangements and unconsolidated structured entities.

These standards are required to be applied for accounting periods beginning on or after January 1, 2013, with earlier adoption permitted. The Company has not yet assessed the impact of these standards or determined whether it will adopt the standards early.

**5. CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS**

The preparation of consolidated financial statements in accordance with IFRS often requires management to make estimates about and apply assumptions or subjective judgment to future events and other matters that affect the reported amounts of the Company’s assets, liabilities, revenue, expenses and related disclosures. Assumptions, estimates and judgments are based on historical experience, expectations, current trends and other factors that management believes to be relevant at the time at which the Company’s consolidated financial statements are prepared. Management reviews, on a regular basis, the Company’s accounting policies, assumptions, estimates and judgments in order to ensure that the consolidated financial statements are presented fairly and in accordance with IFRS.

Critical accounting estimates and judgments are those that have a significant risk of causing material adjustment and are often applied to matters or outcomes that are inherently uncertain and subject to change. As such, management cautions that future events often vary from forecasts and expectations and that estimates routinely require adjustment.

Management considers the following areas to be those where critical accounting policies affect the significant judgments and estimates used in the preparation of the Company’s consolidated financial statements.

**Estimated useful life**

The management assesses fixed assets in line with the assets useful life. The amount and the related fixed assets amortization timetable for a given period are influenced by their estimated useful life. The estimations are reviewed at least once a year and are updated if the useful life expectations are altered by physical wear, technical and commercial obsolescence.

**Intangible assets**

The values associated with identifiable intangible assets with finite lives are determined by applying significant estimates and assumptions.



**NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS  
FOR THE THREE-MONTH AND SIX-MONTH PERIODS ENDED NOVEMBER 30, 2011 ET 2010  
(unaudited)**

**5. CRITICAL ACCOUNTING ESTIMATES AND JUDGMENTS (CONT.)**

Valuations performed in connection with post-acquisition assessments of impairment of identifiable intangible assets are based on estimates that include risk-adjusted future cash flows. Projected cash flows are based on business forecasts, trends and expectations and are therefore inherently judgmental. Future events could cause the assumptions utilized in impairment assessments to change, resulting in a potentially significant effect on the Company's future operating results due to increased impairment charges, or reversals thereof, or adjustments to amortization charges.

**Fair value of stock options**

Determining the fair value of the stock options requires judgment related to the choice of a pricing model, the estimation of stock price volatility and the expected term of the underlying instruments. Any changes in the estimates or inputs utilized to determine fair value could result in a significant impact on the Company's future operating results or other components of shareholders' equity.

**Government assistance**

The Company is entitled to government assistance in the form of research and development tax credits and grants. These are applied against related expenses and the cost of the asset acquired. Tax credits are available based on eligible research and development expenses consisting of direct and indirect expenditures and including a reasonable allocation of overhead expenses. Grants are subject to compliance with terms and conditions of the related agreements. Government assistance is recognized when there is reasonable assurance that the Company has met the requirements of the approved grant program or, with regard to tax credits, when there is reasonable assurance that they will be realized.

**6. BUSINESS ACQUISITION**

On February 10, 2011, the Company acquired 100% of the shares of Praxis Santé Inc., a private company which develops software applications that enhances all aspects of the prescription filling process and the complete pharmacists patient file management "PraxisLab". PraxisLab uses up-to-date Web technology which is perfectly compatible with the technology used by the Company. Compensation included a cash payment of \$800,000 and the issuance of 3,500,000 shares at a fair value of \$647,500.

The excess of the purchase price over the fair value of net identifiable assets totaling \$1,163,802 was recognized as intellectual property.

The acquisition has been accounted using the purchase method and, accordingly, the results of operations have been included in the consolidated financial statements from the date of acquisition.

The estimated fair value of the net identifiable assets acquired is attributed as follows:

<b>Current assets</b>	<b>\$</b>
Cash	14,405
Accounts receivable and other receivables	72,145
	<hr/> 86,550
Fixed assets	13,560
Development costs	193,069
Intellectual property	1,163,802
	<hr/> 1,456,981
<b>Total assets</b>	<b>1,456,981</b>
 <b>Current Liabilities</b>	
Accounts payable and accrued liabilities	9,481
	<hr/> 9,481
<b>Total liabilities</b>	<b>9,481</b>
 <b>Net assets acquired</b>	 <b>1,447,500</b>



**NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS  
FOR THE THREE-MONTH AND SIX-MONTH PERIODS ENDED NOVEMBER 30, 2011 ET 2010  
(unaudited)**

**7. ACCOUNTS RECEIVABLE**

	November 30, 2011	May 31, 2011	June 1, 2010
	\$	\$	\$
Accounts receivable	1,405,642	75,911	315,906
Research and development tax credits <sup>(1)</sup>	134,993	134,993	82,300
Sales tax receivable	-	-	13,442
	<b>1,540,635</b>	<b>210,904</b>	<b>411,648</b>

<sup>(1)</sup>The precise receivable amount will be known when Revenu Quebec will process and approve the claim. Approved amount could differ from the recorded amount.

**8. FIXED ASSETS**

	Furniture	Computer equipment	Computer equipment for ZRx Prescriber	Leasehold improvements	Total
	\$	\$	\$	\$	\$
<b>Cost</b>					
As at May 31, 2011	148,038	230,538	1,776,721	61,586	2,216,883
Acquisitions	1,550	4,649	37,608	-	43,807
Disposals	-	(15,858)	(85,889)	-	(101,747)
As at November 30, 2011	149,588	219,329	1,728,440	61,586	2,158,943
<b>Accumulated amortization</b>					
As at May 31, 2011	127,541	184,247	1,403,182	57,558	1,772,528
Amortization	7,183	11,309	111,458	1,510	131,460
Disposals	-	(13,695)	(82,885)	-	(96,550)
As at November 30, 2011	134,724	181,861	1,431,785	59,068	1,807,438
<b>Net book value at November 30, 2011</b>	<b>14,864</b>	<b>37,468</b>	<b>296,655</b>	<b>3,518</b>	<b>351,505</b>

	Furniture	Computer equipment	Computer equipment for ZRx Prescriber	Leasehold improvements	Total
	\$	\$	\$	\$	\$
<b>Cost</b>					
As at June 1, 2010	145,578	203,604	1,696,131	61,586	2,106,899
Acquisitions	1,540	22,634	283,629	-	307,803
Business acquisition	920	12,640	-	-	13,560
Disposals	-	(8,340)	(203,038)	-	(211,378)
As at May 31, 2011	148,038	230,538	1,776,722	61,586	2,216,884
<b>Accumulated amortization</b>					
As at June 1, 2010	106,891	167,106	1,216,930	48,395	1,539,322
Amortization	20,650	23,456	315,009	9,163	368,278
Disposals	-	(6,315)	(128,757)	-	(135,072)
As at May 31, 2011	127,541	184,247	1,403,182	57,558	1,772,528
<b>Net book value at May 31, 2011</b>	<b>20,497</b>	<b>46,291</b>	<b>373,540</b>	<b>4,028</b>	<b>444,356</b>



**NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS**  
**FOR THE THREE-MONTH AND SIX-MONTH PERIODS ENDED NOVEMBER 30, 2011 ET 2010**  
(unaudited)

**9. INTANGIBLE ASSETS**

	Website	Software	Licenses and rights	Intellectual properties	Development costs	Total
	\$	\$	\$	\$	\$	\$
<b>Cost</b>						
As at May 31, 2011	26,200	4,322	175,000	3,417,737	2,221,605	5,844,864
Acquisitions	-	-	-	-	318,534	318,534
Disposals	-	-	-	-	-	-
As at November 30, 2011	26,200	4,322	175,000	3,417,737	2,540,139	6,163,398
<b>Accumulated Amortization</b>						
As at May 31, 2011	26,200	4,322	175,000	1,043,365	1,651,092	2,899,979
Amortization	-	-	-	170,887	25,088	195,975
Disposals	-	-	-	-	-	-
As at November 30, 2011	26,200	4,322	175,000	1,214,252	1,676,180	3,095,954
<b>Net book value at November 30, 2011</b>	-	-	-	2,203,485	863,959	3,067,444
<b>Cost</b>						
As at June 1, 2010	26,200	4,322	175,000	2,253,933	1,786,273	4,245,728
Acquisitions	-	-	-	-	320,066	320,066
Business acquisition	-	-	-	1,163,802	250,261	1,414,063
Disposals	-	-	-	-	(134,993)	(134,993)
As at May 31, 2011	26,200	4,322	175,000	3,417,735	2,221,607	5,844,864
<b>Accumulated Amortization</b>						
As at June 1, 2010	26,200	4,322	175,000	788,877	1,458,499	2,452,898
Amortization	-	-	-	254,488	192,593	447,081
Disposals	-	-	-	-	-	-
As at May 31, 2011	26,200	4,322	175,000	1,043,365	1,651,092	2,899,979
<b>Net book value at May 31, 2011</b>	-	-	-	2,374,370	570,515	2,944,885

During fiscal year 2011, the Company applied tax credits, totalling \$77,377 (\$68,400 in 2010), as a reduction of capitalized development costs.

**10. ACCOUNTS PAYABLE**

	November 30, 2011	May 31, 2011	June 1, 2010
	\$	\$	\$
Accounts payable and accrued liabilities	281,305	513,365	332,425
Wages and deductions at source	365,915	339,423	308,630
Sales tax	57,852	55,416	-
	705,072	908,204	641,055





**NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS  
FOR THE THREE-MONTH AND SIX-MONTH PERIODS ENDED NOVEMBER 30, 2011 ET 2010  
(unaudited)**

**11. CONVERTIBLE DEBENTURE**

On September 30, 2011, the Company has issued a secured convertible debenture for a principal amount of \$1,500,000, such convertible debenture being convertible at the sole option of the holders thereof into common shares of the share capital of the Company on the basis of one common share for each \$0.15 in principal amount of convertible debenture. Furthermore, 10,000,000 common shares purchase warrants were issued. Each warrant entitles the holder thereof to purchase one common share at a price of \$0.15 per share for 24 months following the closing date. The convertible debenture matures 24 months from the date of issuance or such earlier date which may be provided for as a redemption feature. Subject to certain conditions, the Company may redeem all or any portion of the convertible debenture upon 30 days written notice to the holders thereof in which case such holders may exercise their conversion rights, in whole or in part, prior to the intended date of redemption. The convertible debenture bears interest at a rate of 15% per annum. The convertible debenture is secured by a charge on the assets of the Company and a promissory note.

**12. INFORMATION ON INCOME**

	November 30, 2011 (3 months)	November 30, 2010 (3 months)	November 30, 2011 (6 months)	November 30, 2010 (6 months)
	\$	\$	\$	\$
<b>a) Revenue:</b>				
Operating revenue	701,014	497,851	1,226,577	1,034,731
Interest income	217	2,975	293	7,089
	<u>701,231</u>	<u>500,826</u>	<u>1,266,870</u>	<u>1,041,820</u>
<b>b) Selling expenses :</b>				
Selling expenses	232,238	178,583	382,114	349,153
Salaries and benefits	155,706	121,191	276,996	237,967
	<u>387,944</u>	<u>299,774</u>	<u>659,110</u>	<u>587,120</u>
<b>c) Administrative expenses :</b>				
Administrative expenses	221,531	308,330	393,530	546,457
Stock-based compensation	74,418	-	74,418	-
Salaries and benefits	147,618	193,379	320,209	405,561
	<u>443,567</u>	<u>501,709</u>	<u>788,157</u>	<u>952,018</u>
<b>d) General operating expenses :</b>				
Operating expenses	21,699	36,311	54,480	73,504
Salaries and benefits	256,027	260,898	530,272	509,626
	<u>277,726</u>	<u>297,209</u>	<u>584,752</u>	<u>583,130</u>
<b>e) Development costs :</b>				
Development costs	5,062	44,524	47,311	86,700
Salaries and benefits	196,696	210,732	408,740	336,223
	<u>201,758</u>	<u>255,256</u>	<u>456,051</u>	<u>422,923</u>
<b>f) Financial expenses:</b>				
Interest and bank charges	5,746	1,536	9,368	5,517
Interest on debenture	37,500	-	37,500	-
Transaction costs	172,173	-	172,173	-
	<u>215,419</u>	<u>1,536</u>	<u>219,041</u>	<u>5,517</u>



**NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS  
FOR THE THREE-MONTH AND SIX-MONTH PERIODS ENDED NOVEMBER 30, 2011 ET 2010  
(unaudited)**

**12. INFORMATION ON INCOME (CONT.)**

	November 30, 2011 (3 months)	November 30, 2010 (3 months)	November 30, 2011 (6 months)	November 30, 2010 (6 months)
	\$	\$	\$	\$
<b>g) Amortization:</b>				
Amortization of fixed assets	88,673	109,575	131,460	154,704
Amortization of development costs	12,546	61,197	25,088	120,291
Amortization of others intangible assets	85,443	56,348	170,887	112,697
	<u>186,662</u>	<u>227,120</u>	<u>327,435</u>	<u>387,692</u>

**13. COMMITMENTS**

- a) As at November 30, 2011, the balance of commitments under operating leases amounts to \$476,507.

Minimum lease payments for each of the next four years are as follows:

	2012	2013	2014	2015
	\$	\$	\$	\$
Leasehold – Head Office	121,132	122,293	122,525	51,400
Leasehold – Toronto	46,067	-	-	-
Leasehold – Montreal	5,200	-	-	-
Multi-function printers	7,013	877	-	-
	<u>179,412</u>	<u>123,170</u>	<u>122,525</u>	<u>51,400</u>

**14. SHARE CAPITAL**

**a) Authorized**

An unlimited number of voting and participating common shares without par value.

**b) Declared**

	November 30, 2011	May 31, 2011	June 1, 2010
	\$	\$	\$
130,474,687 common shares as at November 30 and May 31, 2011, and 110,841,785 as at June 1, 2010.	<u>25,438,120</u>	<u>25,438,120</u>	<u>23,001,758</u>

**c) Transactions during the period ended November 30, 2011.**

No transactions occurred during the six-month period ended November 30, 2011.



**NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS  
FOR THE THREE-MONTH AND SIX-MONTH PERIODS ENDED NOVEMBER 30, 2011 ET 2010  
(unaudited)**

**14. SHARE CAPITAL (CONT.)**

**d) Transaction during 2011**

The Company completed a private placement for gross proceeds of \$2,500,600, issuing 16,132,902 units at a price of \$0.155 per unit.

- On February 9, 2011, the Company completed a first closing of a private placement, for gross proceeds of \$1,992,600 issuing 12,855,483 units of the Company at a price of \$0.155 per unit. Each unit is comprised of one common share in the share capital of the Company and one-half of one common share purchase warrant. Each whole warrant gives the holder the right to purchase one common share at a price of \$0.17 for a period of 24 months. The Company granted an 8% cash commission to the agents and a number of warrants to purchase units equal to 8% of the total number of units sold under the offering at a price of \$0.155 per unit.

- As at March 28, 2011, the Company completed its private placement for gross proceeds of \$508,000, issuing 3,277,419 units at a price of \$0.155 per unit. Each unit is comprised of one common share in the share capital of the Company and one-half of one common share purchase warrant. Each whole warrant gives the holder the right to purchase one common share at a price of \$0.17 for a period of 24 months. An 8% cash commission was paid to the agents and the Company granted warrants to purchase units equal to 8% of the total number of units sold under the offering at a price of \$0.155 per unit.

On February 10, 2011, the Company acquired 100% of the outstanding shares of Praxis Santé Inc. Compensation included a cash payment of \$800,000 and the issuance of 3,500,000 shares at a fair value of \$647,500.

The fair value of the units awarded to agents during the fiscal year 2011 was estimated on the grant date using the Black-Scholes pricing model with the following assumptions:

Date	May 31, 2011	
	March 28, 2011	February 9, 2011
Quantity	262,193	1,028,439
Stock price	\$0.155	\$0.155
Dividend yield	Nil	Nil
Expected volatility	90%	90%
Risk-free interest rate	1.75%	1.87%
Expected life	24 months	24 months

Fees paid to agents in relation to the private placement represented a \$120,099 share issue cost during the fiscal year 2011.

**e) Share capital reconciliation**

	Number	Declared \$
Balance as at June 1, 2010	110,841,785	23,001,758
Private placement issue (February & March 2011)	16,132,902	1,788,862
Business acquisition issue (February 2011)	3,500,000	647,500
<b>Balance as at May 31, 2011</b>	<b>130,474,687</b>	<b>25,438,120</b>
	-	-
<b>Balance as at November 30, 2011</b>	<b>130,474,687</b>	<b>25,438,120</b>



**NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS  
FOR THE THREE-MONTH AND SIX-MONTH PERIODS ENDED NOVEMBER 30, 2011 ET 2010  
(unaudited)**

**14. SHARE CAPITAL (CONT.)**

**f) Escrowed shares**

In accordance with the requirements of the TSX Venture Exchange, all of the 18,000,000 issued common shares from the reverse takeover were held in escrow under a security escrow agreement.

Under the terms of the agreement, no percentage of common shares held in escrow were released upon publication of the Final Exchange Bulletin and 5% of the original number of escrowed common shares were released on a six-month intervals on the 6<sup>th</sup>, 12<sup>th</sup>, 18<sup>th</sup>, 24<sup>th</sup> and 10% were released on the 30<sup>th</sup>, 36<sup>th</sup>, 42<sup>nd</sup>, 48<sup>th</sup>, 54<sup>th</sup>, 60<sup>th</sup>, 66<sup>th</sup> and 72<sup>nd</sup> following the initial release. The escrowed agreement ended August 8, 2011.

As at May 31, 2011, 1,800,000 common shares were still held in escrow.

**15. STOCK OPTION PLAN**

The shareholders of the Company approved a resolution modifying the stock option plan from a 10% "fixed" stock option plan to a 10% "rolling" stock option plan as described in the management proxy circular for the annual and special meeting of shareholders held November 25, 2011. Under the plan terms, the exercise price of the options will be determined by the Directors of the Company subject to other restrictions described in the plan and some requirements of the TSX Venture Exchange. The maximum period for which an option can be exercise is limited to five years and the exercise price must be paid in full before the issuance of the shares.

The following table summarizes the changes in the plan position for the period ended November 30, 2011 and the fiscal year ended May 31, 2011:

	Options	Average exercise price
		\$
Balance as at June 1, 2010	9,721,500	0.31
Awarded	3,207,500	0.20
Cancelled	(2,735,000)	0.24
<b>Balance as at May 31, 2011</b>	<b>10,194,000</b>	<b>0.29</b>
Awarded	4,740,000	0.15
Cancelled	(1,916,500)	0.20
<b>Balance as at November 30, 2011</b>	<b>13,017,500</b>	<b>0.25</b>



**NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS  
FOR THE THREE-MONTH AND SIX-MONTH PERIODS ENDED NOVEMBER 30, 2011 ET 2010  
(unaudited)**

**15. STOCK OPTION PLAN (CONT.)**

The following table summarizes the information about the outstanding stock options for the period ended November 30, 2011 and the fiscal year ended May 31, 2011.

**a) As at November 30, 2011**

Outstanding options			Exercisable options	
Number	Weighted average remaining contractual life (months)	Weighted average exercise price	Number	Weighted average exercise price
		\$		\$
150,000	2	0.25	150,000	0.25
3,037,500	5	0.50	3,037,500	0.50
2,415,000	20	0.20	2,415,000	0.20
100,000	36	0.32	100,000	0.32
2,540,000	49	0.20	2,540,000	0.20
35,000	49	0.20	35,000	0.20
4,740,000	60	0.15	<sup>(1) (2)</sup> 4,740,000	0.15
13,017,500	37	0.25	13,017,500	0.25

<sup>(1)</sup>The 4,740,000 stock options issued under this plan are subject to transfer restrictions for a period of four months from the grant date.

<sup>(2)</sup> 570,000 stock options awarded to employees are held in escrow by the Company and will be released according to set objectives.

**Transactions during the period ended November 30, 2011.**

On November 2011, the Company granted 4,740,000 options which entitle the holders to purchase 4,740,000 common shares at an exercise price of \$0.15 per share for a period of five years.

The fair value of the stock options awarded during the period ended November 30, 2011 was estimated on the grant date using the Black-Scholes' options pricing model with the following assumptions:

	<b>November 30, 2011</b>
Date	November 30, 2011
Quantity	4,740,000
Stock price	\$0.075
Dividend yield	Nil
Expected volatility	45%
Risk-free interest rate	1.46%
Expected life	60 months

The non-recurrent stock-based compensation expense amounts to \$74,418 for the six-month period ended November 30, 2011.



**NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS  
FOR THE THREE-MONTH AND SIX-MONTH PERIODS ENDED NOVEMBER 30, 2011 ET 2010  
(unaudited)**

**15. STOCK OPTION PLAN (CONT.)**

b) As at May 31, 2011

Number	Outstanding options		Exercisable options	
	Weighted average remaining contractual life (months)	Weighted average exercise price	Number	Weighted average exercise price
989,000	1	\$0.20	989,000	\$0.20
640,000	6	\$0.20	640,000	\$0.20
150,000	8	\$0.25	150,000	\$0.25
3,037,500	11	\$0.50	3,037,500	\$0.50
2,575,000	26	\$0.20	2,575,000	\$0.20
100,000	39	\$0.32	100,000	\$0.32
100,000	39	\$0.20	100,000	\$0.20
2,567,500	55	\$0.20	2,567,500	\$0.20
35,000	55	\$0.20	35,000	\$0.20
<b>10,194,000</b>	<b>25</b>	<b>\$0.29</b>	<b>10,194,000</b>	<b>\$0.29</b>

**Transaction during 2011**

On December 2010, the Company granted 3,207,500 options which entitle the holder to purchase 3,207,500 common shares at an exercise price of \$0.20 per share for a period of five years.

The fair value of the stock options awarded during 2011 was estimated on the grant date using the Black-Scholes' options pricing model with the following assumptions:

Date	May 31, 2011	
	December 13, 2010	December 16, 2010
Quantity	3,172,500	35,000
Stock price	\$0.17	\$0.17
Dividend yield	Nil	Nil
Expected volatility	90%	90%
Risk-free interest rate	2.49%	2.49%
Expected life	60 months	60 months

The non-recurrent stock-based compensation expense amounts to \$370,787 for the fiscal year ended May 31, 2011.



**NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS  
FOR THE THREE-MONTH AND SIX-MONTH PERIODS ENDED NOVEMBER 30, 2011 ET 2010  
(unaudited)**

**16. WARRANTS**

The following table summarizes the changes in the plan position for the three-month period ended November 30, 2011 and the fiscal year ended on May 31, 2011.

	Warrants	Weighted average Exercise price	Value
		\$	\$
Balance as at June 1, 2010	13,205,747	0.35	1,794,661
Warrants expired	(13,205,747)	0.35	(1,794,661)
Awarded to investors	8,066,452	0.17	711,737
Awarded to brokers	645,316	0.17	56,939
<b>Balance as at May 31, 2011</b>	<b>8,711,768</b>	<b>0.17</b>	<b>768,676</b>
Awarded to the debenture holders	10,000,000	0.15	-
<b>Balance as at November 30, 2011</b>	<b>8,711,768</b>	<b>0.17</b>	<b>768,676</b>

**a) Transactions during the period ended November 30, 2011.**

On September 30, 2011, in connection with the convertible debenture, the Company issued 10,000,000 warrants; each warrant entitles the holders thereof to purchase one common share at a price of \$0.15 per share for 24 months following the closing date.

The following table summarizes the information about the outstanding warrants owned by public investors and agents as at November 30, 2011.

Number	Outstanding warrants	
	Weighted average remaining contractual life (months)	Weighted average exercise price \$
6,427,742	15	0.17
514,219	15	0.17
1,638,710	16	0.17
131,097	16	0.17
10,000,000	22	0.15
<b>18,711,768</b>	<b>19</b>	<b>0.16</b>

**b) Transaction during 2011**

On July 8, 2010, 13,205,747 warrants, with an exercise price of \$0.35 each, have expired. These warrants were cancelled and the total carrying value, which was \$1,794,661, was transferred to the contributed surplus.

On February 9, 2011, the Company completed a first closing of a private placement, for gross proceeds of \$1,992,600 issuing 12,855,483 units of the Company at a price of \$0.155 per unit. Each unit is comprised of one common share in the share capital of the Company and one-half of one common share purchase warrant. Each whole warrant gives the holder the right to purchase one common share at a price of \$0.17 for a period of 24 months. The Company granted an 8% cash commission to the agents and a number of warrants to purchase units equal to 8% of the total number of units sold under the offering at a price of \$0.155 per unit.



**NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS  
FOR THE THREE-MONTH AND SIX-MONTH PERIODS ENDED NOVEMBER 30, 2011 ET 2010  
(unaudited)**

**16. WARRANTS (CONT.)**

As at March 28, 2011, the Company completed its private placement for gross proceeds of \$508,000, issuing 3,277,419 units at a price of \$0.155 per unit. Each unit is comprised of one common share in the share capital of the Company and one-half of one common share purchase warrant. Each whole warrant gives the holder the right to purchase one common share at a price of \$0.17 for a period of 24 months. An 8% cash commission was paid to the agents and the Company granted warrants to purchase units equal to 8% of the total number of units sold under the offering at a price of \$0.155 per unit.

The following table summarizes the information about the outstanding warrants owned by public investors and agents as at May 31, 2011.

Number	Outstanding warrants	
	Weighted average remaining contractual life (months)	Weighted average exercise price
		\$
6,427,742	21	0.17
514,219	21	0.17
1,638,710	22	0.17
131,097	22	0.17
<b>8,711,768</b>	<b>21</b>	<b>0.17</b>

**17. FINANCIAL INSTRUMENTS**

**Fair value**

The fair value of cash, accounts receivable and accounts payable is equal to their carrying amount given their forthcoming maturities.

Section 3862, "Financial Instruments – Disclosures and presentation", was amended to require additional disclosure regarding fair value measurements, including a three level hierarchy that reflects the significance of the inputs used in making the fair value measurements. The three level of hierarchy regarding fair value measurements are as follows:

- Level 1 – Unadjusted quoted prices in active markets for identical assets and liabilities;
- Level 2 – Inputs, other than quoted prices, for which assets or liabilities are directly or indirectly observable;
- Level 3 – Inputs that are not based on observable market data.

As at November 30, 2011, May 31, 2011 and June 1, 2010, all assets and liabilities were classified in level 1.

**Credit risk management**

The Company extends credit to its customers in normal course of business. Ongoing credit assessments are conducted and the balance sheet reflects the allowance for doubtful accounts. No qualitative assessment was conducted, since the management believes the credit risk is immaterial.

**Interest rate risk management**

The Company does not have any variable rate debt. Furthermore, the Company invests some of its cash in financial instruments bearing guaranteed interest. These financial instruments represent a minimal risk for the Company.





**NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS  
FOR THE THREE-MONTH AND SIX-MONTH PERIODS ENDED NOVEMBER 30, 2011 ET 2010  
(unaudited)**

---

**17. FINANCIAL INSTRUMENTS (CONT.)**

**Market risk**

The future performance of the Company is dependent on the continued popularity of its existing products and its ability to develop and introduce products that gain acceptance and satisfy consumer preferences in targeted markets. The popularity of any of its products may decline over time as consumer preferences change or as new competing products are introduced in targeted markets. The development of new systems and their distribution within the targeted market, require significant investments.

**Liquidity risk**

In order to meet additional capital requirements, the Company may consider collaborative arrangements and additional public or private financing to fund all or a part of particular product development programs. Private financing could include the incurrence of debt and the issuance of additional equity securities, which could result in dilution to shareholders. There can be no assurance that additional funding will be available. The Company manages this risk by establishing detailed cash forecasts, as well as long-term operating and strategic plans. According to these forecasts, most of its cash flows for operating activities will be generated by pharmaceutical corporations and pharmacies contracts for the use of the e-Pic network.

**Key personnel risk**

Recruiting and retaining qualified personnel is essential to the Company's success. The Company believe that it has been successful in recruiting excellent personnel to help it meet their objectives but, as its activities grow, it is possible that additional key personnel in departments like; administration, research and development, as well as marketing will be required. Although the Company believe that it will be successful in attracting qualified personnel, there can be no assurance to that effect.

**18. CAPITAL DISCLOSURES**

In regards to capital management, the Company's objective, from the beginning of its operations, is the continuity of its operations in order to carry on with the development and marketing of the e-Pic network, the protection of its assets, while maximizing the shareholders return on investment. The company is not subject to any externally imposed capital requirements. The Company has several options regarding its capital needs. See Note 17 for more details.

The Company defines its capital as the sum of its shareholders equity and long-term debts. The shareholders equity (\$1,682,000 as at November 30, 2011, \$3,375,258 as at May 31, 2011 and \$3,827,243 as at June 1, 2010) includes: share capital, warrants, contributed surplus and deficit. Long-term debts account for \$1,500,000 as at November 30, 2011 and were nonexistent, as at May 31, 2011 and June 1, 2010. The capital decrease of \$1,693,259 during the period ended November 30, 2011 is the result of the deficit of the period.

**19. RELATED PARTY TRANSACTIONS**

**a) Key management compensation**

Key management is those persons having authority and responsibility for planning, managing and controlling the Company's activities, including the Directors and Executives. Key management participates to the stock option plan. Key management wage compensation, for the six-month periods ended November 30, 2011 and 2010 totalize \$300,000. Furthermore, as at November 30, 2011, 690,000 stock options, at a price of \$0.15 for a period of 5 years, were awarded to key management and represent a stock-based compensation cost of \$10,833.



**NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS  
FOR THE THREE-MONTH AND SIX-MONTH PERIODS ENDED NOVEMBER 30, 2011 ET 2010  
(unaudited)**

---

**19. RELATED PARTY TRANSACTIONS (CONT.)**

**b) Related party transactions**

During the six-month period ended November 30, 2011, the Company paid professional fees totaling \$43,260 (\$43,260 in 2010) to a corporation owned by a shareholder and officer of the Company. Accounts payable include an amount of \$14,420 for the six-month period ended November 30, 2011 and \$21,630 for the six-month period ended November 30, 2010.

**Related party transactions terms and conditions**

The balances, as at the end of the period, are not guaranteed and bear no interest, as it is a cash settlement. No guaranties were given or received regarding receivables or payables between the related parties. For the six-month periods ended November 30, 2011 and 2010, the Company did not record any depreciation as regards to outstanding related party receivables. An assessment is performed at each financial period, by examining the related party financial statements and the market in which the related party operates.

**20. TRANSITION TO IFRS**

The Company' consolidated interim financial statements have been prepared in accordance with IFRS, as described in notes 2 and 3. This is the Company's first year to produce consolidated financial statements under IAS 34 and IFRS 1 "First-time Adoption of IFRS". The Company's adoption date is June 1, 2011, and the consolidated financial statements reporting date in November 30, 2011. However, the Company's IFRS transition date is June 1, 2010, being the first comparative period. The Company prepared its opening IFRS statement of financial position at that date.

IFRS1 is based on the principle that the adoption of IFRS should be applied retrospectively. However, IFRS 1 offers certain optional exemptions and mandatory exceptions to the retrospective application of IFRS to first-time preparers of IFRS financial statements. Those exemptions and exceptions, which are relevant to the Company, are discussed in turn below.

**IFRS EXEMPTION OPTIONS**

**Business combinations** – IFRS 1 allows an entity to apply IFRS 3, Business Combinations either retrospectively to all combinations, retrospectively from a certain point forward or prospectively to acquisitions occurring after the Company's transition date (June 1, 2010). The Company has elected to apply IFRS 3 prospectively. Therefore, business combinations prior to June 1, 2010 were not reclassified.

**Share-based Payments** – IFRS 1 - encourages application of its IFRS 2 - *Share-based payments* provision to equity instruments granted on or before November 7, 2002, but also permits the application of IFRS 2, only to equity instruments granted after November 7, 2002 that had not vested by the Transition Date. The Company elected to avail itself of the exemption provided under IFRS 1 and therefore applied IFRS 2 only to all equity instruments granted after January 1, 2006 that had not vested by the Transition Date.

**Designation of previously recognized financial instruments** – IFRS 1 permits to re-designate financial instruments previously recognized, provided that the financial asset or liability meets certain criteria in IAS 39 - Financial Instruments: Recognition and Measurement. The company decided to maintain its financial instruments designation.

**Fair or reassessment value as deemed cost** – IFRS 1 permits to assess its fixed assets at their fair value as at transition date and subsequently use the fair value as deemed cost. The company decided not to reassess its fixed assets at fair value as at transition date.



**NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS  
FOR THE THREE-MONTH AND SIX-MONTH PERIODS ENDED NOVEMBER 30, 2011 ET 2010  
(unaudited)**

**20. TRANSITION OF IFRS (CONT.)**

**IFRS MANDATORY EXCEPTIONS**

**Accounting estimates** – In accordance with IFRS 1, the estimates recognized according with IFRS as at the transition date must be coherent with the estimates recognized, at the same date, according with earlier GAAP, after adjustments to reflect any difference between the accounting methods, unless objective evidences show that these estimates were incorrect. Thereby, the first-time adopter can not use information retrospectively in order to recognize or modify accounting estimates. The prior recognised estimates by the Company, in accordance with Canadian GAAP, were not modified, except if necessary in order to reflect any difference between both methods.

**RECONCILIATION BETWEEN IFRS AND CANADIAN GAAP**

IFRS 1 requires to explain the transition impact from earlier GAAP to IFRS of its financial position, its financial performance and its cash flows. Consequently, the Company must disclose the reconciliations as at June 1, 2010, November 30, 2010 and also May 31, 2011 regarding its equity, and as at May 31, 2011 and November 30, 2011 regarding its comprehensive income. It should be noted that the transition from GAAP to IFRS did not have a significant impact on the Company's generated cash flows.

The following information presents the reconciliations between Canadian GAAP and IFRS regarding balances and required periods.

**Reconciliation of equity**

	Notes	May 31, 2011	November 30, 2010	June 1, 2010
		\$	\$	\$
Equity – GAAP Canadian		4,231,897	2,759,133	4,681,892
Intangible assets – future income taxes	a)	(682,000)	(682,000)	(682,000)
Amortization	b)	(174,639)	(149,862)	(172,649)
Equity – IFRS		3,375,258	1,927,271	3,827,243

**Reconciliation of statements of comprehensive loss**

	For the six-month period ended November 30, 2010			
	Canadian GAAP	Note	Adjustments	IFRS
	\$		\$	\$
Revenue	1,040,552		-	1,040,552
Operating expenses excluding amortization	2,549,440		-	2,549,440
Amortization	410,478	c)	(22,787)	387,691
Net loss and comprehensive loss	(1,919,366)		22,787	(1,896,579)

**Reconciliation of statements of comprehensive loss**

	For the fiscal year ended May 31, 2011			
	Canadian GAAP	Note	Adjustments	IFRS
	\$		\$	\$
Revenue	2,883,008		-	2,883,008
Operating expenses excluding amortization	5,769,445		-	5,769,445
Amortization	813,369	c)	1,989	815,358
Net loss and comprehensive loss	(3,699,806)		(1,989)	(3,701,795)



**NOTES TO INTERIM CONSOLIDATED FINANCIAL STATEMENTS  
FOR THE THREE-MONTH AND SIX-MONTH PERIODS ENDED NOVEMBER 30, 2011 ET 2010  
(unaudited)**

---

**20. TRANSITION OF IFRS (CONT.)**

**a) Intangible assets** – Canadian GAAP previously allowed the Company to increase the intellectual property cost by its related future income taxes, while IFRS does not. A \$682,000 unamortized amount was recorded against equity and the related intangible asset as at the transition date. As a result of this change, the related intellectual property accumulated amortization was reduced by an amount of \$238,700. The net result, as at the transition date, represents a \$443,300 intangible asset net book value and deficit increase.

**b) Fixed assets** – IFRS requires that the amount of amortization of an asset be distributed systematically over its useful life and that the amortization method reflects the rate at which the company expects to consume the future economic benefits related to the asset. Those requirements were less explicit in Canadian GAAP.

IFRS specifies that strait-line amortization leads to a constant charge over the useful life of the asset, if the asset residual value does not change. The Company assessed that, according to this definition, strait-line amortization method best reflects the rate at which the company expects to consume the future economic benefits related to its fixed assets.

The cumulative impact of changing from the declining method (Canadian GAAP) to the strait-line method (IFRS) has reduced by \$481,539 the carrying value of fixed assets as a result of the same amount increase in cumulated amortization, as at the transition date, along with a deficit increase.

**c) Amortization** – For the six-month period ended November 30, 2010, the adoption of the new amortization method has generated a \$22,787 decrease and a \$1,989 increase for the fiscal year ended May 31, 2011.

